Richard Petrucci, MD

Richard Petrucci, MD is the Chief Medical Officer for COPE Health Solutions (CHS).  He joined CHS in April 2025 and brings years of experience in both the Health Plan and Provider arenas.

Prior to joining COPE Health Solutions, he served as the Chief Medical Officer at SOMOS Innovation. He had been in that position since December of 2021. SOMOS is an IPA in the South Bronx of New York City dedicated to delivering the highest quality care to the most vulnerable communities in New York City. His focus there was on building programs to improve health care in the community of the South Bronx. He oversaw the care delivered by over 1000 PCPs.

Prior to joining SOMOS, Dr. Petrucci had multiple roles at WellCare Health Plans. He served as the Chief Medical Officer for the WellCare NY Market, beginning in January of 2018. He was responsible for all clinical market focused activities related to Quality Improvement, Network Management and Care Management.

From February 2015 to January 2018 he was WellCare’s Corporate Chief Medical Director, Quality. In that role, he led the corporate quality data analytics, quality clinical improvement and quality accreditation teams resulting in improved STAR score performance across the company.  At WellCare, he also served as the New York State Market Medical Director, where he successfully improved the NY market’s Medicare and Medicaid quality scores.

He began his career and spent 6 years as a practicing primary care physician (PCP) and physician leader in the Kaiser Permanente Medical Group. He then joined Oxford Health Plans as a physician executive leading the development of quality and care management programs. He has subject matter expertise in all facets of managed care, including disease management, quality management, physician profiling, NCQA accreditation and chronic care management for Medicaid, Medicare and commercial lines of business.

Before returning to the managed care industry, Dr. Petrucci spent 8 years in the pharmaceutical industry developing insulin products for diabetics. He spent 3 years with Sanofi US where he was the clinical lead for the insulin product Lantus and subsequently spent 5 years with MannKind Corp. where he was responsible for the development and FDA approval of the inhaled insulin product Afrezza.

Dr. Petrucci earned a bachelor’s degree from Williams College in Williamstown, Massachusetts and a Doctor of Medicine degree from the New York Medical College in Valhalla, New York. Dr. Petrucci is board certified in internal medicine. He remains interested in diabetes care and is an active supporter of the American Diabetes Association.